Busulfan
- Generic Name
- Busulfan
- Brand Names
- Busulfex, Myleran, Busulfan Fresenius Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C6H14O6S2
- CAS Number
- 55-98-1
- Unique Ingredient Identifier
- G1LN9045DK
- Background
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According t...
- Indication
For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing...
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 242
- Registration Number
- NCT05453552
- Locations
- 🇨🇳
Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 430
- Registration Number
- NCT05327023
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2022-07-01
- Target Recruit Count
- 64
- Registration Number
- NCT05303727
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05293509
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Ossium Health, Inc.
- Registration Number
- NCT05170828
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
- Conditions
- Interventions
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 54
- Registration Number
- NCT05027945
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Guenther Koehne
- Target Recruit Count
- 20
- Registration Number
- NCT04982354
- Locations
- 🇺🇸
Miami Cancer Institute at Baptist Health of South Florida, Miami, Florida, United States
Outcomes of Patients After Allo-HSCT With Decitabine and NAC
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2021-06-30
- Target Recruit Count
- 100
- Registration Number
- NCT04945096
Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)
- Conditions
- Interventions
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- St. Petersburg State Pavlov Medical University
- Target Recruit Count
- 50
- Registration Number
- NCT04942730
- Locations
- 🇷🇺
RM Gorbacheva Research Institute, Saint Petersburg, Russian Federation
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
- Conditions
- Interventions
- Drug: BusulfanRadiation: Total-body irradiationDrug: MelphalanDrug: CyclophosphamideDrug: FludarabineProcedure: PBSC Hematopoietic Stem Cell Transplantation (HSCT)Procedure: Bone Marrow Hematopoietic Stem Cell TransplantationDrug: Post-transplant CyclophosphamideDrug: MesnaDrug: TacrolimusDrug: Mycophenolate MofetilOther: Patient-Reported Outcomes
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2024-05-23
- Target Recruit Count
- 300
- Registration Number
- NCT04904588
- Locations
- 🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States
🇺🇸Ohio State Medical Center, James Cancer Center, Columbus, Ohio, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.